Emergency Department
Blood/Body Fluid Exposure Instructions

For employees sent to the Emergency Department after hours to be evaluated for needle stick / body fluid exposure

1. Floor or unit Charge RN where employee was exposed will print this entire packet.
2. Complete sections you are responsible for as designated in top right hand corner.
3. Patient then takes entire packet to the ED for review and treatment as appropriate. Call the ED charge RN at 925-6117 to alert them that you are sending a patient.
4. Patient will be discharged from the ED after #3 above to follow up with Employee Health Clinic on the next business day.
Blood/Body Fluid Exposure Checklist

After Hours

- **Patient** = person exposed (usually the employee)
- **Source / Donor** = from whom the fluid came

<table>
<thead>
<tr>
<th>Task</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fill out source (donor) information sheet for the ED to use in assessing exposure risk</td>
<td></td>
</tr>
<tr>
<td>Have employee fill out body fluid exposure assessment (2 pages)</td>
<td></td>
</tr>
<tr>
<td>Send employee with above paperwork and rest of the printed packet to the ED</td>
<td></td>
</tr>
<tr>
<td>Draw blood on source (donor) if applicable</td>
<td></td>
</tr>
<tr>
<td>Do not draw any blood on the employee</td>
<td></td>
</tr>
</tbody>
</table>

Area Charge Nurse
Complete before sending employee to the ED
Body Fluid Source (DONOR) 
Assessment Instructions

1. **Obtain Source Name, MR# and Location** (This is the person who’s fluid exposed the employee or pt).
   - If the Source is under 9 months of age, do the Risk Assessment on the mother and draw Source labs from the mother.
   - **Complete Source Medical History Review**
   - **Look up any available lab results for HIV, Hepatitis C, and Hepatitis B.**
     - If HIV, Hep C and/or Hep B (HBsAg) were done in the past 2 weeks or if prior HIV, Hepatitis B or Hepatitis C positive then **do not** repeat that test. Obtain results for the provider.
   - If blood was drawn for other reasons/studies, use those samples if they are still in the lab and order the lab panel.
   - Review Medical Record (answer the Source Assessment questions from medical records and from a Source interview if appropriate).
   - Consent is needed to test for HIV, but is not needed for Hepatitis C or HbsAg testing.

2. **Obtain Source HIV testing consent.**
   - If Source is conscious and competent, interview the Source to obtain signed HIV testing consent.
   - If the Source is unable to give consent (including anyone under the legal age for consent), follow New Mexico state law on obtaining HIV consent. Assistance from Epidemiology, Occupational Health, or HSC Legal Counsel may be obtained.
   - If you are able to make contact only by phone, HIV Consent may be obtained but must be repeated by the Source to a 2nd staff witness.

3. **Order source HIV, Hepatitis C, and Hepatitis B (HbsAg)**—order as “**Needle Don**” lab panel.

4. **Provide the source information to the evaluating provider**

5. **Refer the source to their primary care physician to obtain the results of their Source Labs**

6. **For afterhours exposure assessments**
   - Notify OHS of all after-hour exposures by calling the clinic the next working day.
   - If “**Donor Lab**” results are needed prior to next Clinic business day then the Administrative Supervisor should obtain the results and relay these to the Recipient’s provider (ED) so that treatment of the recipient may be modified as needed.

**Source / Donor Assessment** (must be completed and sent to ED for evaluation)

<table>
<thead>
<tr>
<th>Source Name:</th>
<th>MRN #:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown Source:</td>
<td>No further source assessment required</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Source with history of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
</tr>
<tr>
<td>Liver disease</td>
</tr>
<tr>
<td>Multiple or SAME sex partners</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Source blood draw</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consent for HIV test obtained</td>
</tr>
<tr>
<td>Nurse or Supervisor</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Body Fluid Exposure Assessment

Name __________________________________ Home Phone ___________________ Cell Phone ___________________
Work Phone ___________________ (Preferred number for clinic to contact: ☐ Home ☐ Work ☐ Cell)
Date of Incident _____________ Time of Incident ______________
Work Department ________________ Job Category __________________
Location of the exposure (ED, Patient room, OR, Lab, etc.) ________________________________

Employee Medical History

Have you ever had? HIV ☐ Yes ☐ No   Hepatitis C ☐ Yes ☐ No   Hepatitis B ☐ Yes ☐ No
Other significant medical history ___________________________________________
Last Tetanus Booster (date) __________
Have you received the Hepatitis B Vaccination? ☐ Yes ☐ No
   If yes, do you know if you are HBV immune / protected? ☐ Yes ☐ No ☐ Unknown

** Is the Source patient (the person’s whose body fluid it was) identifiable? ** ☐ Yes ☐ No ☐ Unknown

Complete #1-11 if NEEDLESTICK or other SHARP OBJECT injury
(Skip to # 12 for blood or body fluid splash/other exposures)

1. Were you the original user of the sharp item? ☐ Yes ☐ No ☐ Unknown
2. Did the sharp item have blood visible on it? ☐ Yes ☐ No ☐ Unknown
3. For what purpose was the sharp item originally used?
   ☐ Unknown ☐ Injection through the skin ☐ Drawing venous/arterial blood
   ☐ IV use: injection into/aspiration from an IV injection site/IV port, connecting or starting IV
   ☐ Placing a central line ☐ Suturing/cutting/electrocautery ☐ Other __________________________
4. How did the injury occur?
   ☐ During use ☐ After use ☐ Recapping needle ☐ Restraining a patient ☐ Preparation for reuse of
   ☐ reusable equipment ☐ Device left on floor, bed or other inappropriate place ☐ While disposing of item
5. What device was involved in the injury?
   ☐ Unknown
   ☐ Hollow bore Needle: Identify (gauge of needle, etc) ________________________________
   ☐ Other sharp: Identify (lancet, suture needle, scalpel, glass, etc.) __________________
5a. Brand/Manufacturer of the sharp item: _______________ Model: _______________
6. Did the item causing the injury have a “safety design” such as retractable or shielded needle?
   ☐ Yes ☐ No ☐ Unknown   If yes, describe feature __________________________
6a. Was the device activated? ☐ Yes, fully activated ☐ Yes, partially activated ☐ No ☐ Unknown
7. What was the physical location of your injury? (ex. Right index finger) ________________
8. Was the injury? ☐ Superficial (little/no bleeding) ☐ Moderate (skin punctured/some bleeding)
   ☐ Severe (deep stick/cut, profuse bleeding)  

Continued on next page

Patient Label
9. If the injury was to the hand, did the sharp item penetrate?
   □ Single pair of gloves □ Double pair of gloves □ No gloves

10. Are you primarily?
    □ Right handed □ Left handed

11. Do you have any opinion as to how this injury could have been prevented?
    ___________________________________________________________

Complete #12-21 for OTHER BLOOD/BODY FLUID Exposure
(Skip to signature if had needlestick or other sharp object injury)

12. Type of Body Fluid: (please check)
    □ Unknown □ Blood □ Other body fluid: list type (Sputum, vomit, etc.)
    If “other,” was visible blood present in the fluid? □ Yes □ No □ Unknown

13. What body part was exposed? (Skin on the right hand, eye, mouth, etc)
    ___________________________________________________________

14. Did the blood/body fluid?
    □ Touch unprotected skin □ Soak through protective garment or clothing

15. What barrier garments were worn at the time of the exposure?
    □ None □ Gloves □ Goggles/eyeshield □ Surgical mask □ Gown/apron/lab coat
    □ Other: ___________________________________________________

16. How did the exposure occur? ____________________________________

17. Did equipment failure occur? □ Yes □ No
    If yes, please specify equipment type and manufacturer:
    ___________________________________________________________

18. How long was the blood/body fluid in contact with your skin/mucous membrane?
    □ Less then 5 minutes □ 5-14 minutes □ 15 minutes to 1 hour □ Over 1 hr

19. Did you flush/clean area? □ Yes □ No
    Comments: ____________________________________________

20. What was the volume of blood/body fluid?
    □ Unknown
    □ Small (up to 1 teaspoon or 5cc) □ Moderate (up to quarter cup or 50cc)
    □ Large (over 50cc)

21. Do you think this injury could have been prevented with controls in place?
    □ Yes □ No
    If yes, please describe: ____________________________________

Employee Signature ____________________________ Date _____________

ED attending to review and sign below:

Comments: ____________________________________________

_____________________________       _____________
ED Provider Date

Patient Label
Blood/Body Fluid Exposure Checklist
After Hours

**Patient** = person exposed (usually the employee)
**Source / Donor** = from whom the fluid came

<table>
<thead>
<tr>
<th>All Patients During ED visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review and <strong>sign</strong> exposure information pages 3-5 filled out by <strong>patient and charge RN</strong>.</td>
</tr>
<tr>
<td>Review and <strong>sign</strong> with the employee the decision trees for HBV, HCV and HIV</td>
</tr>
<tr>
<td>• Check off flowchart boxes as appropriate</td>
</tr>
<tr>
<td>• Complete gray shaded boxes and sign in the provider line</td>
</tr>
<tr>
<td>• <strong>Circle</strong> the HIV risk status and discuss CDC recommendations</td>
</tr>
<tr>
<td>• Review risks / side effects of PEP if warranted</td>
</tr>
<tr>
<td>• Offer Hep B vaccination if not already vaccinated or known non-responder</td>
</tr>
<tr>
<td><strong>Draw source / donor labs if that person is also an ED patient</strong> (order = “Needle Don”)</td>
</tr>
<tr>
<td><strong>Refer to Employee Health Clinic next business day</strong></td>
</tr>
<tr>
<td><strong>Discharge patient from the ED with the last sheet of this packet and ED “Needlestick” computerized discharge instructions from First Net</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient decides <strong>NO</strong> to HIV PEP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NO LABS</strong> drawn on patient in the ED</td>
</tr>
<tr>
<td><strong>Refer patient to Employee Health Clinic next business day for CONFIDENTIAL blood draw of HIV and hepatitis panel</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient decides <strong>YES</strong> to HIV PEP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Complete consent sheet</strong></td>
</tr>
<tr>
<td>Review risks / side effects of PEP</td>
</tr>
<tr>
<td><strong>Patient to sign</strong> consent for treatment form</td>
</tr>
<tr>
<td><strong>Give patient copy of consent</strong></td>
</tr>
<tr>
<td><strong>Draw CBC, Chem 7, LFT, amylase, pregnancy test (if applicable)</strong></td>
</tr>
<tr>
<td><strong>(DO NOT draw HIV or hepatitis panel in ED)</strong></td>
</tr>
<tr>
<td><strong>Start first dose (after pregnancy test) of PEP in ED and give Take Home Pack of remaining PEP doses to patient (all meds are in ED Pyxis)</strong></td>
</tr>
<tr>
<td><strong>Patient referred to appropriate clinic (on discharge sheet) next business day for CONFIDENTIAL blood draw of HIV and hepatitis panel</strong></td>
</tr>
<tr>
<td><strong>NON – hospital employees</strong> (ex. kid stuck with syringe at park) <strong>should</strong> have HIV, hepatitis panel, CBC, chem 7, LFT, amylase and PGU (if appropriate) drawn in the ED. These patients should have follow up with PCP 1 week after starting PEP.</td>
</tr>
</tbody>
</table>
**Hepatitis B**

**Decision Tree**

**POST EXPOSURE PROPHYLAXIS - Hepatitis B**

1. **Unvaccinated recipient OR vaccine series not completed by recipient**
   - **Give HBV vaccine now. (2)**
   - **Plus**
   - **Obtain Donor HepBsAg Results**

   - **Hep B Sag Unknown (or unknown donor)**
   - **Hep B Sag (+)**
   - **Hep B Sag (-)**

   - **HBIG (3)**

   - **No further action**

2. **Vaccinated recipient**
   - **Response to Vaccine - Unknown**
   - **Obtain Hep SAg results on Donor within 24 hrs; if unable, consider HBIG if Donor high risk**

   - **Recipient Titer > 10 mlU/ml**
   - **No further action**

   - **Recipient Titer < 10 mlU/ml**
   - **1 Booster Dose HVB vaccine (4)**
   - **HBIG if Donor is Hep B sAg positive**

3. **Documented Non Responder (Recipient of 6 vaccinations without titer response)**
   - **Documented response to vaccine**
   - **Obtain Donor HepBsAg Results**

   - **Hep B Sag (+)**
   - **Hep B Sag (-)**

   - **No further action if titer was obtained within the past year. Consider obtaining repeat recipient titer if not within the past year. Then give one booster vaccination if titer is low.**

**Risk of seroconversion is dependent upon many factors and is between 2 and 40% in an unvaccinated recipient**

**NON** - health care workers with exposure should receive vaccination
### Hepatitis B Vaccination Guidelines

**TABLE 3. Recommended postexposure prophylaxis for exposure to hepatitis B virus**

<table>
<thead>
<tr>
<th>Vaccination and antibody response status of exposed workers</th>
<th>Source HBsAg positive</th>
<th>Source HBsAg negative</th>
<th>Source unknown or not available for testing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unvaccinated</strong></td>
<td>HBIG¹ x 1 and initiate HB vaccine series¹</td>
<td>Initiate HB vaccine series</td>
<td>Initiate HB vaccine series</td>
</tr>
<tr>
<td><strong>Previously vaccinated</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Known responder**</td>
<td>No treatment</td>
<td>No treatment</td>
<td>No treatment</td>
</tr>
<tr>
<td>Known nonresponder²**</td>
<td>HBIG x 1 and initiate revaccination or HBIG x ²²</td>
<td>No treatment</td>
<td>If known high risk source, treat as if source were HBsAg positive</td>
</tr>
<tr>
<td>Antibody response unknown</td>
<td>Test exposed person for anti-HBs⁴⁴ ¹ 1. If adequate, ** no treatment is necessary 2. If inadequate, ** administer HBIG x 1 and vaccine booster</td>
<td>No treatment</td>
<td>Test exposed person for anti-HBs ¹ 1. If adequate, ¹ no treatment is necessary 2. If inadequate, ¹ administer vaccine booster and recheck titer in 1–2 months</td>
</tr>
</tbody>
</table>

---

* Persons who have previously been infected with HBV are immune to reinfection and do not require postexposure prophylaxis.

¹ Hepatitis B surface antigen.

² Hepatitis B immune globulin; dose is 0.06 mL/kg intramuscularly.

³ Hepatitis B vaccine.

** A responder is a person with adequate levels of serum antibody to HBsAg (i.e., anti-HBs ≥10 mIU/mL).

²² A nonresponder is a person with inadequate response to vaccination (i.e., serum anti-HBs < 10 mIU/mL).

¹ The option of giving one dose of HBIG and reinitiating the vaccine series is preferred for nonresponders who have not completed a second 3-dose vaccine series. For persons who previously completed a second vaccine series but failed to respond, two doses of HBIG are preferred.

⁴ Antibody to HBsAg.
Hepatitis C
Decision Tree

Check Boxes upon Completion:

- Addendum L

POST EXPOSURE DECISION PROTOCOL - HEPATITIS C

1. Check Donor

a. Donor Unknown
   - Offer Follow-up Hep C (by Elisa) to recipient at 6 months and 12 months

b. Donor Known
   - Offer to the recipient follow up testing for Hepatitis C antibodies (by Elisa) at 6 and 12 months

   - Offer the recipient follow up testing for Hepatitis C by PCR at 4 - 6 weeks * if high risk exposure. Refer to Gastroenterology if positive for possible therapy.

   - Offer to the recipient follow up testing for Hepatitis C antibodies (by Elisa) Antibodies at 6 and 12 months

- Counsel the recipient on Hepatitis C and the risk of seroconversion.

Risk of seroconversion in percutaneous exposure to blood is 1.8%.

Patient Label

Health Provider Signature

Date

* If the recipient is not tested before 3 months post-exposure, proceed with the Elisa rather than the PCR.
HIV
Decision Tree

HIV POST EXPOSURE PROPHYLAXIS (PEP) DECISION PROTOCOL

(1) Utilize the CDC PEP recommendation tables if needed.
(2) HIV testing on recipient is done at 0 weeks, 6 weeks, 12 weeks, 26 weeks, and 52 weeks.
(3) CBC, Diff, HFP, Amylase, BUN, CR and pregnancy test are the baseline labs.

These labs (excluding pregnancy test) could be held until the Source HIV is known.

Medications should be started as soon as possible, ideally within 2 hours.

prescription guidelines on back side.

Check if treatment initiated:
- Pregnancy test obtained on women before initiating prophylaxis.
- Baseline labs obtained (3)
- Treatment consent obtained from the Recipient before initiating treatment.
- Recipient counseled and Prescription Guidelines followed.

OR
- Recipient declined HIV PEP

Risk of seroconversion in percutaneous exposure to blood is 0.3% (3 per 1000)
Risk of seroconversion in a mucous membrane exposure to blood is 0.09% (<1 per 1000)
Risk of seroconversion in a non-intact skin exposure is felt to be < 0.09%

These are for HIV infected blood. Risk of seroconversion with exposure to any other fluid or tissue is felt by the CDC to be considerably lower but has not been quantified.

NON - health care worker with exposure: Consider likelihood for HIV prevalence in exposure to determine need for PEP (4 weeks duration). Patient will need PCP follow up.
**HIV Exposure Risk**

PEP Recommendations (from CDC)

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th>HIV Positive</th>
<th>Unknown HIV Status (Known Source)</th>
<th>Unknown HIV Status (Unknown Source)</th>
<th>HIV negative</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Percutaneous Exposures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less severe</td>
<td>Basic 2-drug PEP; Call Infectious Disease</td>
<td>Generally, no PEP warranted.</td>
<td>May consider basic 2-drug PEP for source with HIV risk factors</td>
<td></td>
</tr>
<tr>
<td>(solid needle, superficial injury)</td>
<td></td>
<td></td>
<td>May consider basic 2-drug PEP if exposure to HIV-infected persons is likely</td>
<td></td>
</tr>
<tr>
<td>More severe</td>
<td>Expanded 3-drug PEP; Call Infectious Diseases for regimen</td>
<td>Generally, no PEP warranted.</td>
<td>May consider basic 2-drug PEP for source with HIV risk factors</td>
<td></td>
</tr>
<tr>
<td>(large-bore hollow needle, deep puncture, visible blood on device, needle used in patient’s artery or vein)</td>
<td></td>
<td></td>
<td>May consider basic 2-drug PEP if exposure to HIV-infected persons is likely</td>
<td></td>
</tr>
<tr>
<td><strong>Mucous Membrane or Non-intact Skin Exposures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small volume</td>
<td>Basic 2-drug PEP; Call Infectious Disease</td>
<td>Generally, no PEP warranted.</td>
<td>May consider basic 2-drug PEP for source with HIV risk factors</td>
<td></td>
</tr>
<tr>
<td>(a few drops)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large volume</td>
<td>Expanded 3-drug PEP; Call Infectious Diseases for regimen</td>
<td>Generally, no PEP warranted.</td>
<td>May consider basic 2-drug PEP for source with HIV risk factors</td>
<td>No PEP warranted</td>
</tr>
<tr>
<td>(major blood splash)</td>
<td></td>
<td></td>
<td>May consider basic 2-drug PEP if exposure to HIV-infected persons is likely</td>
<td></td>
</tr>
</tbody>
</table>

If donor is HIV + and on multiple medications, ID attending (via PALS) **should be** consulted for best regimen. ID is happy to consult on all cases with ED attending questions.
## HIV PEP

### Medication Information for Providers

<table>
<thead>
<tr>
<th>Basic Regimen</th>
<th>Truvada®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtricitabine (FTC) 200 mg / Tenofovir (TDF) 300 mg</td>
<td></td>
</tr>
</tbody>
</table>

#### Preferred Dosing
One tablet by mouth once daily with or without food

#### Available Dosages
Tablet, 200 mg FTC + 300 mg TDF  
(Take Home Packs in ED PYXIS)

#### Advantages
- Well tolerated
- Once daily dosing
- FTC and TDF are active against HBV
- Pregnancy category

#### Disadvantages
- Headache
- GI intolerance (diarrhea, nausea, vomiting, and flatulence)
- Renal insufficiency (Fanconi’s syndrome)

### Expanded Regimen
Atazanavir® (ATZ) + Ritonovir® (RTV)

#### Preferred Dosing
ATZ: One tablet by mouth once daily with food
RTV: One tablet by mouth once daily with food  
(take together with ATZ)

#### Available Dosages
ATZ: Tablet, 300 mg  
RTV: Tablet, 100 mg  
(Take Home Packs in ED PYXIS)

#### Advantages
- One of the preferred HIV regimens
- Generally well-tolerated
- Pregnancy category B

#### ATZ
- Indirect hyperbilirubinemia, with elevated transaminases
- Cannot be taken with proton pump inhibitor; use caution with antacids and H2RAs
- Prolonged PR interval
- Nephrolithiasis
- Possible increased bleeding episodes in hemophiliacs

#### RTV
- Multiple drug interactions with other medications (consult with pharmacist)
- GI intolerance
- Circumoral and extremity parasthesias (rare when used as boosting agent)
- Asthenia

---

If other medications are advised by ID, further information is available (online) in:
“Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis” MMWR Recommendations and Reports Vol 54/No. RR-9, September 30, 2005

---

Patient Label
CONSENT
Post-exposure Prophylaxis for HIV

I may have been exposed to HIV, the virus that causes AIDS, in my work place. The risk of infection from my exposure is not known. However, should HIV infection occur, the outcome is likely to be ultimately fatal. My clinician has offered me treatment with Tenofovir and Emtricitabine (in a combination form known as Truvada®) and, in some cases, Atazanavir/ritonavir, which might reduce my risk of infection. There is no proof that drug treatment after HIV exposure will prevent infection. I will be asked to use contraception during the four weeks of treatment and four subsequent weeks (both men and women). I will be tested for pregnancy and if I am pregnant, any decision to continue prophylaxis will be made in conjunction with an infectious diseases and obstetric clinician. I will be asked to contact my clinician immediately if I learn that I am pregnant while I am on the medications. See table below for risks and side effects associated with antiretroviral drugs. A full listing is in the package insert for each medication. Treatment side effects are expected to disappear after treatment is stopped, but could be life threatening or irreversible. New or rare serious side effects, including cancer, birth defects, or other life-threatening diseases, might develop now or in the future.

<table>
<thead>
<tr>
<th>MEDICATION</th>
<th>COMMON SIDE EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emtricitabine / Tenofovir = Truvada®</td>
<td>Abdominal pain</td>
</tr>
<tr>
<td></td>
<td>Anorexia</td>
</tr>
<tr>
<td></td>
<td>Anxiety</td>
</tr>
<tr>
<td></td>
<td>Arthralgia</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir = Reyataz®</td>
<td>Abdominal pain</td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir = Norvir®</td>
<td>Abdominal pain</td>
</tr>
<tr>
<td></td>
<td>Anorexia</td>
</tr>
<tr>
<td></td>
<td>Asthenia</td>
</tr>
<tr>
<td></td>
<td>Constipation</td>
</tr>
<tr>
<td></td>
<td>Insomnia</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Caution is to be used with other medication use so I understand I need to disclose all medications that I am currently using.

DOSING:
- **Truvada** (Emtricitabine 200 mg / Tenofovir 300 mg): One tablet by mouth once daily x 28 days
- **Atazanavir 300 mg**: One tablet by mouth once daily x 28 days
- **Ritonavir 100 mg**: One tablet by mouth once daily x 28 days

Please read and check each box as appropriate:
- ☐ I understand that I will be taking [ ] Truvada (Emtricitabine/Tenofovir) [ ] Atazanavir / Ritonavir
- ☐ I have been advised to use other antiretroviral drugs {as listed here: ______________________} by an Infectious Disease physician and have been informed of their side effects and drug interactions.
- ☐ I have read the “Informed Consent Information: Post-Exposure HIV Prophylaxis”. I have had the opportunity to ask questions. I further understand that should I have any questions about my treatment I may contact the clinic or the infectious disease consultant.
- ☐ I have discussed all my current medications with my treating provider.

SIGNATURE: _______________________________ DATE: ___ / ___ /___

WITNESS: _________________________________ DATE: ___ / ___ /___

ED Attending
If PEP to be given
Body Fluid Exposure Discharge Information

1. There is a possibility that you have become exposed to one or more of the following diseases:

   **HIV**: Risk of infection through a needlestick is 0.3% (3 per 1000)
   Risk of infection by blood in the eyes or mouth is 0.09% (Less than 1 per 1000)
   Risk of infection by exposure to blood through a break in the skin is felt to be even less.

   These are for HIV infected **blood**. Risk of infection with exposure to any other body fluid is considerably lower.

   **Hepatitis B**: Risk of infection is dependent upon many factors and is between 2 and 40% in an unvaccinated person.

   **Hepatitis C**: Risk of infection after a needlestick is 1.8%.
   There have been no cases of Hepatitis C infection from blood exposure to the eyes or mouth.

2. Report symptoms of fever, enlarged and tender lymph nodes, skin rash, stomach or nerve problems which start 2-6 weeks after this exposure.

3. It is possible that you could transmit one or more of these diseases to another person, so you should avoid activities that might expose others to your blood or body fluids. These include sharing toothbrushes or razorblades, donating blood or body organs, breastfeeding or becoming pregnant. If you are sexually active, you should consider using condoms with sexual activity. If you are a user of recreational drugs, you should not share needles. These precautions are especially important in the first 6-12 weeks after this exposure.

4. If you have received HIV prophylaxis medication (PEP), make sure that you received a copy of the consent form with information on the drug side effects and drug interactions, and an explanation of the need to continue the PEP regimen.

- **Hospital employees** should follow up at **OHS** (Occupational Health Services – 272-2517 – 5th floor) between 7:30 am and 3:30 pm the next business day.

- **UNM faculty or residents** should follow up at **EOHS** (Employee Occupational Health Services – 272-8043 – 2nd floor of the Family Practice Building) between 8:00 am and 5:00 pm the next business day.

- **Medical or other students** should follow up at **SHAC** (Student Health and counseling – 277-3136 – South Campus across from the SUB building) between 8:00 am and 5:00 pm the next business day.

- Individuals who were exposed while at work should contact their employer immediately.

- **Other members of the community** should follow up with a Primary Care Provider in 1 week to discuss following the blood drawn in the emergency department.